Lavie Bio Announces Commercial Expansion of Yalos® as Seed-Treatment for Soybean, Following Successful Field Trials
Portfolio Pulse from
Lavie Bio, a subsidiary of Evogene Ltd., announced the commercial expansion of its product Yalos® as a seed-treatment for soybeans, following successful field trials. Sales are expected to begin in the US during the 2025 spring season.
November 12, 2024 | 12:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Evogene Ltd.'s subsidiary, Lavie Bio, is set to expand its product Yalos® as a seed-treatment for soybeans, with sales starting in the US in 2025. This expansion follows successful field trials, potentially boosting Evogene's revenue and market presence in the ag-biologicals sector.
The announcement of Yalos® expansion into the soybean market is significant for Evogene as it could lead to increased revenues and market share in the ag-biologicals sector. The successful field trials and planned US launch in 2025 indicate a positive outlook for the product's adoption.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80